Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib

JournalMethodologyMIDDPharmacometricsProgram strategies and efficienciesRegulatory interactionsRespiratorySpecial considerationsSpecial/specific populations